MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyag196

Медицинская библиотека · The oncologist · 2026

Treatment outcomes of trastuzumab-based chemotherapy in patients with HER2-positive gastric cancer: a nationwide retrospective cohort study.

Kim Tae-Hwan, Lee Eunyoung, Choi Yong Won, Ahn Mi Sun, Kang Seok Yun, Choi Jin-Hyuk, Lee Hyun Woo

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Trastuzumab-based chemotherapy is the standard first-line treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic gastric cancer (GC). However, evidence on real-world outcomes according to the chemotherapy backbone remains limited.

METHODS

A total of 2399 patients with GC treated with trastuzumab-based chemotherapy were analyzed, of whom 486 patients were treated with trastuzumab/5-fluorouracil/cisplatin (HFP) and 1913 patients were treated with trastuzumab/capecitabine/cisplatin (HXP). Time to subsequent treatment (TST) and overall survival (OS) were analyzed according to the type of chemotherapy backbone.

RESULTS

With a median follow-up of 10.5 months, the median TST was 6.08 months (95% confidence interval [CI], 5.65-6.60) in the HFP group and 8.02 months (95% CI, 7.72-8.57) in the HXP group (P < .0001). The median OS was 9.89 months (95% CI, 8.94-10.87) for the HFP group and 13.27 months (95% CI, 12.75-14.00) for the HXP group (P < .0001). Specifically, HXP followed by trastuzumab and capecitabine maintenance (HXP-HX) demonstrated the best outcomes with median TST of 13.44 months (95% CI, 12.52-15.61) and median OS of 22.18 months (95% CI, 20.83-24.44) compared with HXP followed by trastuzumab maintenance (HXP-H) and HXP alone (both P < .0001), which were also significant in multivariable analysis.

CONCLUSIONS

Trastuzumab/capecitabine/cisplatin followed by trastuzumab/capecitabine maintenance showed the best survival outcomes for patients with locally advanced unresectable or metastatic HER2-positive GC based on real-world big data analysis of the Trastuzumab for Gastric Cancer regimen, suggesting that HXP-HX is recommended over HXP-H. In the current immunotherapy era for HER2-positive GC, the potential role of capecitabine maintenance as part of combination strategies should be interpreted cautiously and warrants further investigation.

Для цитирования: Kim Tae-Hwan, Lee Eunyoung, Choi Yong Won, Ahn Mi Sun, Kang Seok Yun, Choi Jin-Hyuk, Lee Hyun Woo. Treatment outcomes of trastuzumab-based chemotherapy in patients with HER2-positive gastric cancer: a nationwide retrospective cohort study.. The oncologist. 2026. DOI: 10.1093/oncolo/oyag196.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.